Intratumoral α-SMA Enhances the Prognostic Potency of CD34 Associated with Maintenance of Microvessel Integrity in Hepatocellular Carcinoma and Pancreatic Cancer

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Wang, Wen Quan ^a,b   Liu, Liang ^a,b   Xu, Hua Xiang ^a,b   Luo, Guo Pei ^a,b   Chen, Tao ^a,b   Wu, Chun Tao ^a,b   Xu, Yong Feng ^a,b   Xu, Jin ^a,b   Liu, Chen ^a,b   Zhang, Bo ^a,b   Long, Jiang ^a,b   Tang, Zhao You ^b   Yu, Xian Jun ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CARBONATE DEHYDRATASE IX; CD34 ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CELL DENSITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MICROVASCULAR INVASION; OVERALL SURVIVAL; PANCREAS CANCER; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; STROMA CELL; TISSUE MICROARRAY; TUMOR INVASION; TUMOR VASCULARIZATION;

ACTINS; ANTIGENS, CD34; CARCINOMA, HEPATOCELLULAR; CELL COUNT; COHORT STUDIES; HUMANS; LIVER NEOPLASMS; MICROVESSELS; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84881124148     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071189     Document Type: Article

References (44)

1. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
2. Carmeliet P, Jain RK, (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473: 298-307.
3. Sun HC, Tang ZY, Li XM, Zhou YN, Sun BR, et al. (1999) Microvessel density of hepatocellular carcinoma: its relationship with prognosis. J Cancer Res Clin Oncol 125: 419-426.
4. Poon RT, Ng IO, Lau C, Yu WC, Yang ZF, et al. (2002) Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 20: 1775-1785.
5. Charpin C, Devictor B, Bergeret D, Andrac L, Boulat J, et al. (1995) CD31 quantitative immunocytochemical assays in breast carcinomas. Correlation with current prognostic factors. Am J Clin Pathol 103: 443-448.
6. Kumar S, Ghellal A, Li C, Byrne G, Haboubi N, et al. (1999) Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 59: 856-861.
7. Uzzan B, Nicolas P, Cucherat M, Perret GY, (2004) Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 64: 2941-2955.
8. Maeda K, Chung YS, Takatsuka S, Ogawa Y, Sawada T, et al. (1995) Tumor angiogenesis as a predictor of recurrence in gastric carcinoma. J Clin Oncol 13: 477-481.
9. Niedergethmann M, Hildenbrand R, Wolf G, Verbeke CS, Richter A, et al. (2000) Angiogenesis and cathepsin expression are prognostic factors in pancreatic adenocarcinoma after curative resection. Int J Pancreatol 28: 31-39.
10. Paradiso A, Ranieri G, Silvestris N, Naccarato G, Bevilacqua G, et al. (2001) Failure of primary breast cancer neoangiogenesis to predict pattern of distant metastasis. Clin Exp Med 1: 127-132.
11. van der Zee JA, van Eijck CH, Hop WC, van Dekken H, Dicheva BM, et al. (2011) Angiogenesis: a prognostic determinant in pancreatic cancer? Eur J Cancer 47: 2576-2584.
12. Thiery JP, Acloque H, Huang RY, Nieto MA, (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890.
13. Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, et al. (2012) The pancreas cancer microenvironment. Clin Cancer Res 18: 4266-4276.
14. Sugimoto H, Mundel TM, Kieran MW, Kalluri R, (2006) Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther 5: 1640-1646.
15. Friedman SL, (2008) Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 88: 125-172.
16. Ju MJ, Qiu SJ, Fan J, Xiao YS, Gao Q, et al. (2009) Peritumoral activated hepatic stellate cells predict poor clinical outcome in hepatocellular carcinoma after curative resection. Am J Clin Pathol 131: 498-510.
17. Cascone T, Heymach JV, (2012) Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword? J Clin Oncol 30: 441-444.
18. Jain RK, Duda DG, Clark JW, Loeffler JS, (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3: 24-40.
19. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, et al. (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91: 1071-1121.
20. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, et al. (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231.
21. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, et al. (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15: 232-239.
22. Cooke VG, LeBleu VS, Keskin D, Khan Z, O'Connell JT, et al. (2012) Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 21: 66-81.
23. Raza A, Franklin MJ, Dudek AZ, (2010) Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am J Hematol 85: 593-598.
24. Mazzone M, Dettori D, Leite de Oliveira R, Loges S, Schmidt T, et al. (2009) Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136: 839-851.
25. Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, et al. (2011) HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 19: 31-44.
26. Johansson A, Hamzah J, Payne CJ, Ganss R, (2012) Tumor-targeted TNFalpha stabilizes tumor vessels and enhances active immunotherapy. Proc Natl Acad Sci U S A 109: 7841-7846.
27. Sun HC, Zhang W, Qin LX, Zhang BH, Ye QH, et al. (2007) Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J Hepatol 47: 684-690.
28. Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, et al. (2008) High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol 26: 2707-2716.
29. Jia JB, Wang WQ, Sun HC, Zhu XD, Liu L, et al. (2010) High expression of macrophage colony-stimulating factor-1 receptor in peritumoral liver tissue is associated with poor outcome in hepatocellular carcinoma after curative resection. Oncologist 15: 732-743.
30. Liu C, Long J, Liu L, Xu J, Zhang B, et al. (2012) Pancreatic stump-closed pancreaticojejunostomy can be performed safely in normal soft pancreas cases. J Surg Res 172: e11-17.
31. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, et al. (2010) AJCC cancer staging manual (7th ed.). New York: Springer.
32. Liu L, Zhu XD, Wang WQ, Shen Y, Qin Y, et al. (2010) Activation of beta-catenin by hypoxia in hepatocellular carcinoma contributes to enhanced metastatic potential and poor prognosis. Clin Cancer Res 16: 2740-2750.
33. Bao B, Groves K, Zhang J, Handy E, Kennedy P, et al. (2012) In vivo imaging and quantification of carbonic anhydrase IX expression as an endogenous biomarker of tumor hypoxia. PLoS One 7: e50860.
34. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, et al. (2000) Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 89: 500-507.
35. Hidalgo M, (2010) Pancreatic cancer. N Engl J Med 362: 1605-1617.
36. Sasajima J, Mizukami Y, Sugiyama Y, Nakamura K, Kawamoto T, et al. (2010) Transplanting normal vascular proangiogenic cells to tumor-bearing mice triggers vascular remodeling and reduces hypoxia in tumors. Cancer Res 70: 6283-6292.
37. Hezel AF, Deshpande V, Zimmerman SM, Contino G, Alagesan B, et al. (2012) TGF-beta and alphavbeta6 Integrin Act in a Common Pathway to Suppress Pancreatic Cancer Progression. Cancer Res 72: 4840-4845.
38. Wang WQ, Liu L, Sun HC, Fu YL, Xu HX, et al. (2012) Tanshinone IIA inhibits metastasis after palliative resection of hepatocellular carcinoma and prolongs survival in part via vascular normalization. J Hematol Oncol 5: 69.
39. Jia JB, Wang WQ, Sun HC, Liu L, Zhu XD, et al. (2011) A novel tripeptide, tyroserleutide, inhibits irradiation-induced invasiveness and metastasis of hepatocellular carcinoma in nude mice. Invest New Drugs 29: 861-872.
40. Leite de Oliveira R, Deschoemaeker S, Henze AT, Debackere K, Finisguerra V, et al. (2012) Gene-targeting of phd2 improves tumor response to chemotherapy and prevents side-toxicity. Cancer Cell 22: 263-277.
41. Zhang W, Sun HC, Wang WQ, Zhang QB, Zhuang PY, et al. (2012) Sorafenib Down-regulates Expression of HTATIP2 to Promote Invasiveness and Metastasis of Orthotopic Hepatocellular Carcinoma Tumors in Mice. Gastroenterology 143: 1641-1649 e1645.
42. Roskoski R Jr, (2007) Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun 356: 323-328.
43. Jain RK, (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7: 987-989.
44. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, et al. (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11: 83-95.